tirzepatide 2.5 mg/0.5ml solution pen-injector EU drug regulator to review Lilly's Mounjaro in multi-dose pen Mounjaro Tirzepatide 2.5mg/0.5mL Injection -

Gallbladder concerns Rapid weight loss increases gallstone risk, and pregnancy itself independently increases gallbladder complications

Supplementary Tables (download XLSX Supplementary Tables 15

For 300 mcg, inject 0.15 mL

S2CID 56403448

Treatment with GLP-1RAs during the initial year typically results in weight loss ranging from 15% to 25% [11,12]

--- This year brought 26 biosimilars that were approved by the FDA A significant portion of them (16) were denosumab biosimilars: 8 biosimilars referencing Prolia (denosumab for osteoporosis) Additional 8 biosimilars referencing Xgeva (denosumab for cancer-related bone disease) The downstream effects compound: Biosimilars typically reduce costs by 15-35% compared to reference products (this can decrease more as additional biosimilar options become available) Price competition benefits the entire therapeutic category Patients who couldn't afford brand therapy now have accessible options Health systems gain formulary flexibility without compromising clinical outcomes --- The 26 biosimilar approvals in 2025 represent thousands of patients gaining affordable access to proven therapies that may have previously been out of reach